Literature DB >> 29425482

To Bind or Not to Bind: Unravelling GPCR Polypharmacology.

Patrick M Sexton1, Arthur Christopoulos2.   

Abstract

Interaction of a single drug with multiple targets through "polypharmacology" is increasingly recognized as necessary for treatment of complex diseases, such as schizophrenia. G protein-coupled receptors (GPCRs) are major medicinal targets, and understanding the structural basis of both GPCR drug selectivity and promiscuity could provide novel avenues for drug development.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29425482     DOI： 10.1016/j.cell.2018.01.018

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  6 in total

Review 1.  The human endogenous metabolome as a pharmacology baseline for drug discovery.

Authors:  Andreu Bofill; Xavier Jalencas; Tudor I Oprea; Jordi Mestres
Journal:  Drug Discov Today       Date:  2019-06-19       Impact factor: 7.851

2.  Ligand Bias and Its Association With Pro-resolving Actions of Melanocortin Drugs.

Authors:  Sara Patruno; Jose Garrido-Mesa; Mario Romano; Mauro Perretti; Trinidad Montero-Melendez
Journal:  Front Pharmacol       Date:  2018-08-14       Impact factor: 5.810

3.  Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor.

Authors:  Melissa F Adasme; Daniele Parisi; Kristien Van Belle; Sebastian Salentin; V Joachim Haupt; Gary S Jennings; Jörg-Christian Heinrich; Jean Herman; Ben Sprangers; Thierry Louat; Yves Moreau; Michael Schroeder
Journal:  PLoS One       Date:  2020-05-27       Impact factor: 3.240

Review 4.  G protein-coupled receptors: structure- and function-based drug discovery.

Authors:  Dehua Yang; Qingtong Zhou; Viktorija Labroska; Shanshan Qin; Sanaz Darbalaei; Yiran Wu; Elita Yuliantie; Linshan Xie; Houchao Tao; Jianjun Cheng; Qing Liu; Suwen Zhao; Wenqing Shui; Yi Jiang; Ming-Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2021-01-08

5.  Drug repurposing improves disease targeting 11-fold and can be augmented by network module targeting, applied to COVID-19.

Authors:  Inés Rivero-García; Miguel Castresana-Aguirre; Luca Guglielmo; Dimitri Guala; Erik L L Sonnhammer
Journal:  Sci Rep       Date:  2021-10-19       Impact factor: 4.379

6.  Pharmacological characterisation of novel adenosine A3 receptor antagonists.

Authors:  Kerry Barkan; Panagiotis Lagarias; Margarita Stampelou; Dimitrios Stamatis; Sam Hoare; Dewi Safitri; Karl-Norbert Klotz; Eleni Vrontaki; Antonios Kolocouris; Graham Ladds
Journal:  Sci Rep       Date:  2020-11-27       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.